This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
by Zacks Equity Research
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
DGXNegative Net Change UHSNegative Net Change EWPositive Net Change HAEPositive Net Change
medical medical-devices
Jobless Claims Increased More Than Expected
by Zacks Equity Research
Jobless Claims Increased More Than Expected
ABTPositive Net Change NFLXNegative Net Change DHIPositive Net Change
home-builder medical tech-stocks
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
ABTPositive Net Change HAEPositive Net Change PODDPositive Net Change GMEDPositive Net Change
earnings medical medical-devices
Is Intuitive Surgical (ISRG) a "Buy" Ahead of Q2 Earnings Announcement?
by Bryan Hayes
The established medical company has surpassed the earnings mark in each of the last four quarters.
ISRGPositive Net Change
earnings healthcare medical medical-devices
Jobless Claims Rise Again, D.R. Horton Posts Strong Quarter
by Mark Vickery
+1.867 million longer-term jobless claims is the highest single-week figure we've seen since November of 2021.
ABTPositive Net Change NFLXNegative Net Change DHIPositive Net Change
earnings home-builder medical pharmaceuticals
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
LXRXNegative Net Change SAVANegative Net Change LXEOPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
by Zacks Equity Research
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
HAEPositive Net Change GMEDPositive Net Change VCYTNegative Net Change HIMSNegative Net Change
medical
5 Broker-Loved Stocks to Keep a Tab On as Inflation Cools
by Maharathi Basu
Investors would do well to monitor stocks like American Axle (AXL), Dana (DAN), AMC Entertainment (AMC), Centene (CNC) and Archer Daniels (ADM) for higher returns.
ADMNegative Net Change AXLNegative Net Change DANNegative Net Change CNCPositive Net Change AMCNegative Net Change
auto-tires-trucks consumer-discretionary consumer-staples medical
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
BAYRYNegative Net Change ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
ANIPPositive Net Change RARENegative Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note
by Zacks Equity Research
QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.
HAEPositive Net Change QGENNegative Net Change GMEDPositive Net Change HIMSNegative Net Change
medical medical-devices
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
NVSNegative Net Change RHHBYNegative Net Change ARVNNegative Net Change
earnings medical pharmaceuticals
Navigate Market Turbulence With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Cool Company (CLCO), Corcept Therapeutics (CORT), TXO Partners (TXO), & JOYY (YY) are well-poised to gain.
CORTPositive Net Change YYPositive Net Change TXONegative Net Change CLCONegative Net Change
medical transportation
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
by Zacks Equity Research
ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.
AMSCPositive Net Change LINCPositive Net Change CORTPositive Net Change ADMAPositive Net Change BTMDNegative Net Change
medical
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
by Zacks Equity Research
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
UNHPositive Net Change CINegative Net Change HIMSNegative Net Change ELVNegative Net Change
earnings medical
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
BSXPositive Net Change ANGOPositive Net Change CORNegative Net Change GMEDPositive Net Change
earnings medical medical-devices
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
UHSNegative Net Change SNNPositive Net Change HOLXPositive Net Change ELVNegative Net Change
medical medical-devices
UnitedHealth Rises on Q2 Earnings Beat: ETFs to Gain
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected second-quarter 2024 results as it breezed past the Zacks Consensus Estimate on both earnings and revenues.
UNHPositive Net Change DIANegative Net Change XLVPositive Net Change IYHPositive Net Change IHFNegative Net Change FHLCPositive Net Change
earnings etfs medical
AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App
by Zacks Equity Research
AMN Healthcare's (AMN) Manager Hub app, part of the ShiftWise Flex platform, revolutionizes workforce management for healthcare organizations with enhanced mobile capabilities and comprehensive insights.
DGXNegative Net Change UHSNegative Net Change DXCMPositive Net Change AMNPositive Net Change
medical medical-devices
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
JNJNegative Net Change BAYRYNegative Net Change ORICNo Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Housing Starts Increased More Than Expected
by Zacks Equity Research
Housing Starts Increased More Than Expected
JNJNegative Net Change UALPositive Net Change AANegative Net Change
airlines medical pharmaceuticals
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
by Zacks Equity Research
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
AZNPositive Net Change LLYPositive Net Change LXRXNegative Net Change
biotechs medical pharmaceuticals
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
PFEPositive Net Change NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change
medical